Bruton tyrosine kinase (BTK) inhibitors have recently gained attention as a potential therapeutic class in ITP, given their ability to modulate B‐cell activation, autoantibody production, and FcγR‐mediated platelet destruction [52, 53]. Here, BTK is linked to autoimmune thrombocytopenic purpura.